ASCO 2024 | Exploring ctDNA in muscle-invasive bladder cancer: future applications and current limitations
Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute in London, UK, discusses the current and potential future applications of circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer (MIBC). He explains that while ctDNA holds promise, it may still be premature to use it routinely in advanced disease settings, as radiological responses currently appear more robust. Prof. Powles emphasizes the importance of exploring more timepoints, technologies, and drug combinations in future studies. Specifically, he highlights the potential of dynamic changes with enfortumab vedotin and pembrolizumab, suggesting that these might offer better surrogate markers of early efficacy than traditional radiological methods. This innovative approach could significantly impact drug development and treatment strategies in advanced disease. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses – AstraZeneca; Ipsen; MSD; Pfizer; Roche
